GSK, Green Cross and SK are ambitious to lead in the tetravalent influenza market
GSK announced on the 22nd that it would launch the domestically first tetravalent influenza vaccine ‘Fluarix Tetra.’ Green Cross and SK Chemicals are also expected to launch tetravalent influenzas by the second half of the year at the earliest. It is forecasted that competition for tetravalent in...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
